Description Conceptus, despite the sound of its name, works to prevent conception, not help it along. The company develops, makes, and markets women's health care products, namely a minimally invasive permanent birth control procedure called Essure. Soft, flexible micro-insert devices are placed in the fallopian tubes without incisions, allowing tissue to grow over them as a barrier for the egg. Essure does not contain hormones and is designed to become effective after three months. Conceptus markets Essure primarily to gynecologists in the US through a direct sales force and internationally through distributors in Australia, Canada, France, Mexico, and the UK, as well as certain countries in South America and the Middle East.